Brooke Hasson

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent <i>Clostridioides difficile</i> Infection

Matthew Sims, Sahil Khanna, Paul Feuerstadt et al. · JAMA Network Open · 2023 · 81 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +13

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109

Kevin W. Garey, Jinhee Jo, Anne J Gonzales-Luna et al. · JAMA Network Open · 2023 · 28 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Prevalence of Comorbid Factors in Patients With Recurrent <i>Clostridioides difficile</i> Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic

Charles S. Berenson, Bret A. Lashner, Louis Y. Korman et al. · Clinical Infectious Diseases · 2023 · 23 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Acute carbohydrate overfeeding: a redox model of insulin action and its impact on metabolic dysfunction in humans

Nawfal W. Istfan, Brooke Hasson, Caroline M. Apovian et al. · American Journal of Physiology-Endocrinology and Metabolism · 2021 · 21 citations · Full text

Life Sciences, Endocrinology, Physiology +16

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool

Christopher McChalicher, Ahmad A. Abdul-Aziz, S Steve Zhou et al. · Open Forum Infectious Diseases · 2022 · 20 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14